Page 13 - Primary Endpoint News Today : Breaking News, Live Updates & Top Stories | Vimarsana

High rate of complete responses in RP1 skin cancer cohorts underscore the potential for profound patient benefit and supports the ongoing registration directed development programs RP2 data confirms the signal with RP1 in anti-PD1 failed melanoma, uveal melanoma and in treating patients whose cancer has metastasized to the liver Announces plans to initiate broad Phase 2 development of RP2 and/or RP3 in tumor types that commonly metastasize to the liver Virtual investor event to be held at 8:00 a

... and commercializing innovative immuno - oncology therapies and precision medicines, today ... It has also been granted Breakthrough Therapy Designation by ...

Pfizer Forward-Looking Statements The information contained in this release is as of March 8, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.  This release contains forward-looking information about a Lyme disease vaccine candidate, VLA15, and a collaboration between Pfizer and Valneva for VLA15, including their potential benefits and a potential phase 3 start, that involves substantial risks and uncertainties that could cause actual results to differ materially from those ex...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Valneva and Pfizer Announce Initiation of Phase 2 Study for Lyme Disease Vaccine Candidate VALNEVAMarch 8, 2021 GMT The Phase 2 study will include both adult and pediatric subjects with an aim to support acceleration of the vaccine candidate’s pediatric program   VLA15 will be  tested at two different schedules (Month 0-2-6 or Month 0-6) receiving the selected dose of 180µg VLA15 is the only Lyme disease vaccine candidate in active clinical development Saint-Herblain (France) and New York, NY, ...

February 23, 2021 Coronary computed tomographic angiography (CTA) may be as good as invasive coronary angiography (ICA) at predicting the long-term risk of adverse events in patients with non-ST-segment elevation acute coronary syndromes, according to a subanalysis of the VERDICT trial. “The key thing is that it's pretty much equivalent whether you do an ICA or you do a CT to define the likelihood of events after the MI,” lead author Klaus F. Kofoed, MD, DmSc (University of Copenhagen, Denmark), told TCTMD. “So that was kind of reassuring that you don't need to do an ICA if you already ...